Provaris Energy Ltd has signed a second non-binding Memorandum of Understanding (MOU) for hydrogen supply from Norway to Germany, leveraging its proprietary compressed hydrogen carriers.
The company has also been working in collaboration with Yinson Production AS to complete the concept design for CO₂ tanks – a milestone that will facilitate the development of liquid CO₂ storage solutions for integration with fixed onshore storage, offshore floating storage, and ship transport.
Brookside Energy Ltd has achieved key milestones in the drilling of the Bruins Well, located in the SWISH Area of Interest (AOI) in the Anadarko Basin, Oklahoma.
The company has completed the running and cementing of the intermediate casing string and landed the wellbore curve within the target bench of the Woodford Shale. This marks the transition from vertical to horizontal drilling, optimally positioning the well within the reservoir to maximise production potential.
Synchronoss Technologies Inc (NASDAQ:SNCR) reported a strong fourth-quarter performance, with revenue growth driven by an increase in cloud subscribers and higher profitability.
The company, which specializes in personal cloud platforms, posted total revenue of $44.2 million for the quarter ended December 31, 2024, up from $41.4 million a year earlier, fueled by a 6% increase in cloud subscribers.
Excellon Resources Inc (TSX:EXN, OTCQB:EXNRF) announced that it has finalized an agreement to acquire Minera CRC SAC, the owner of the past-producing Mallay Silver Mine and the Tres Cerros exploration property in Peru.
This deal, reached with Adar Mining Corp and Premier Silver Corp, ensures Excellon will take full ownership of Minera CRC through a court-supervised process designed to resolve prior disputes.
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced that the first patient has been dosed in its Phase 2 Elumina trial of VLS-01, the company’s oral transmucosal film formulation of DMT applied to the buccal surface, in participants with treatment-resistant depression.
Topline results are expected from the first treatment phase of the trial in the first quarter of 2026.
Abacus Life Inc (NASDAQ:ABL) announced on Tuesday that it has rebranded as Abacus Global Management, a move aimed at reflecting its broadened global presence and diversified financial services portfolio.
The alternative asset manager said the rebrand underscores its strategic focus on technology-driven financial solutions, spanning life insurance assets, wealth management, and institutional investment services.
Fineqia International Inc (CSE:FNQ, OTC:FNQQF) has announced the cross-listing of its Fineqia FTSE Cardano Enhanced Yield (YADA) Exchange Traded Note (ETN) on the Stuttgart Stock Exchange in Germany.
Issued by Fineqia AG, this ETN is the first of its kind to leverage decentralized finance (DeFi) protocols to generate yield using crypto assets.
Chill Brands Group PLC (LSE:CHLL, OTCQB:CHBRF) is to raise £1 million via convertible loan notes, with proceeds earmarked to support its strategic growth plan for 2025.
The injection of funds is expected to drive ongoing development, launch, and distribution of new rechargeable, reuseable and compliant pod-based vaping products, along with an expanded marketing plan for the chill.com marketplace.
KEFI Gold and Copper PLC (AIM:KEFI, OTC:KFFLF) told investors that the Tulu Kapi project in Ethiopia is ‘proceeding as anticipated’, with a key financing milestone due in the coming weeks.
Credit committee approval has been granted by both of its lending banks, and the remaining procedural steps are expected to be completed by 31 March.
Zephyr Energy PLC (AIM:ZPHR, OTCQB:ZPHRF) chief executive Colin Harrington called 2024 “another strong year” for the firm’s non-operated production assets in the Williston basin, in North Dakota.
Sales from the Williston Basin averaged 1,149 barrels of oil equivalent per day (boepd) net to Zephyr in the year, up from 1,116 boepd in FY 2023.
Synairgen PLC (AIM:SNG, OTC:SYGGF) is set to become the latest in a growing wave of smaller companies leaving London’s AIM market after struggling to lock down fresh investment.
The biotech firm, which has been developing an inhaled treatment for respiratory infections, confirmed plans to cancel its listing and go private after failing to meet fundraising targets.
Hemogenyx Pharmaceuticals PLC (LSE:HEMO, OTC:HOPHF) has secured £709,200 in fresh investment from an institutional backer keen to support its ongoing clinical trials.
The funding, at £1.80 per share, will help advance the company’s experimental cancer treatment, HG-CT-1, which is being tested on patients with a hard-to-treat form of leukaemia called relapsed/refractory acute myeloid leukaemia.
Clinical-stage oncology company Prescient Therapeutics Ltd says its chair Steven Engle is set to retire from the Board on March 30 after more than a decade in the role.
The Board has elected current non-executive director Dr James Campbell to succeed Engle as chair, effective the same date.